B. Metzler seel. Sohn & Co. Holding AG Acquires New Stake in Certara, Inc. (NASDAQ:CERT)

B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Certara, Inc. (NASDAQ:CERT - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor purchased 129,198 shares of the company's stock, valued at approximately $1,513,000. B. Metzler seel. Sohn & Co. Holding AG owned 0.08% of Certara at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Blue Trust Inc. acquired a new stake in shares of Certara during the second quarter worth about $26,000. Innealta Capital LLC purchased a new stake in Certara during the 2nd quarter valued at approximately $36,000. KBC Group NV lifted its position in Certara by 48.2% during the 3rd quarter. KBC Group NV now owns 4,873 shares of the company's stock worth $57,000 after acquiring an additional 1,584 shares during the period. Intech Investment Management LLC purchased a new position in shares of Certara in the 2nd quarter valued at approximately $152,000. Finally, Algert Global LLC acquired a new position in shares of Certara in the second quarter valued at approximately $156,000. 73.96% of the stock is owned by hedge funds and other institutional investors.

Certara Price Performance

NASDAQ:CERT traded up $0.59 during trading hours on Friday, hitting $10.36. The company's stock had a trading volume of 1,595,745 shares, compared to its average volume of 1,092,893. Certara, Inc. has a 52-week low of $9.41 and a 52-week high of $19.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 2.86 and a current ratio of 2.86. The business's 50-day moving average is $10.79 and its two-hundred day moving average is $13.19. The company has a market capitalization of $1.67 billion, a PE ratio of -51.80, a PEG ratio of 4.94 and a beta of 1.51.

Certara (NASDAQ:CERT - Get Free Report) last announced its quarterly earnings data on Wednesday, November 6th. The company reported $0.13 EPS for the quarter, beating the consensus estimate of $0.11 by $0.02. The firm had revenue of $94.80 million during the quarter, compared to analysts' expectations of $95.51 million. Certara had a negative net margin of 8.34% and a positive return on equity of 3.43%. The business's revenue for the quarter was up 10.7% compared to the same quarter last year. During the same quarter last year, the business earned $0.06 earnings per share. As a group, research analysts anticipate that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Insider Transactions at Certara

In other news, insider Leif E. Pedersen sold 51,224 shares of Certara stock in a transaction on Monday, September 9th. The stock was sold at an average price of $11.29, for a total transaction of $578,318.96. Following the completion of the transaction, the insider now owns 99,704 shares of the company's stock, valued at $1,125,658.16. The trade was a 33.94 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, insider Patrick F. Smith sold 5,409 shares of the stock in a transaction dated Monday, October 7th. The shares were sold at an average price of $11.03, for a total transaction of $59,661.27. Following the completion of the sale, the insider now directly owns 50,091 shares in the company, valued at approximately $552,503.73. The trade was a 9.75 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Corporate insiders own 2.39% of the company's stock.

Wall Street Analysts Forecast Growth

CERT has been the subject of several recent research reports. UBS Group raised Certara from a "neutral" rating to a "buy" rating and set a $16.00 price target for the company in a report on Friday, September 27th. Barclays cut their price objective on shares of Certara from $14.00 to $12.00 and set an "equal weight" rating for the company in a research report on Thursday, November 7th. Finally, Robert W. Baird lowered their target price on shares of Certara from $18.00 to $13.00 and set a "neutral" rating on the stock in a report on Tuesday, November 5th. Six research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, Certara currently has an average rating of "Hold" and a consensus price target of $15.92.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.